Jaume Amat, CEO of Rob Surgical, is at the head of the innovative company specialized in precision surgery. Its new Bitrack System surgical robot is in the final phase for certification and has already successfully completed its first operations on live patients.
“It is the entry point in the final stretch of the certification process. It will allow us, by mid-2024, to have the robot certified and make our purpose, which is to universalize precision surgery, a reality.” declares Jaume Amat after the success of the first interventions at the Hospital Clínic.
The Rob Surgical team has been in charge of the project from the conceptualization phase to the present. “The surgical robot technology is 100% in-house. We are the owners of the entire mechanical solution, the electronics, the software… and, therefore, we have a very deep knowledge of the system, which has allowed us to be very flexible and agile in development.” confirms the CEO of the company.
Since its inception, Jaume Amat’s career has been linked to the MEDTECH and BIOTECH sector. After graduating as a Technical Telecommunications Engineer from the Ramon Llull-La Salle University, he completed his training with the IESE Management Development Program (PDD-2009), the Auckland Business School’s Motivation and Leadership Program and the Leadership Program Social of ESADE.
His career is full of challenges and innovative projects. He was part of the founding team of Archivel Farma, a company dedicated to developing a vaccine against Latent Tuberculosis Infection and, as general director, he led the formation of the team and the raising of public and private financing. During this period, a vaccine manufacturing plant was built, it was registered as a Pharmaceutical Laboratory and the Phase I clinical studies of the RUTI vaccine were successfully carried out.
In 2010, he founded Bioemprèn, a consultancy specialized in advising scientists and accompanying them to turn their research work into valuable companies. From Bioemprèn he participated in the creation of more than 10 renowned companies such as Aniling, GoodGut acquired by Hipra, Manremyc, PatConsult and VCN Biosciences.
His adventure with Rob Surgical began in 2012, being part of the founding team of the company and assuming the general direction from the first moment. “The project was born at the university and by a group of engineers who are experts in robotics. They did the exercise of rationalizing what a surgical robot should be like that would respond to the needs of surgeons and at the same time be able to improve the shortcomings that were observed in surgical robotics at the time.”
Jaume Amat, motivated by the challenge, did not hesitate to immerse himself fully in the project of the new surgical robot. “The process was carried out by expert surgeons and many surgeries were attended to analyze the movements of the surgeon and his team during surgical procedures.”
In addition to assuming the direction of Rob Surgical, Jaume Amat also directs and is founder of SPECIPIG, a preclinical CRO specialized in the porcine model, and was president of CataloniaBio & HealthTech, with more than 240 companies and knowledge-generating entities.
